For covid-19: for site-directed mutagenesis, gene synthesis, and plasmid prep
Ended Purchase Order Awarded Last action
- Contract number
- 75N93021P01324
- Awardee
-
Geneimmune Biotechnology Corp UEI TKVTR8LCJB33
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $151,620
Award facts
- Opportunity
-
- Gene synthesis, site-directed mutagenesis and plasmid prep Pre-Solicitation · NOINIAID2085696 · Posted Aug 20, 2021
- Contract value 100% obligated
- $151,620.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Derwood, MD 20855, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $151,620 |
About this award
This is a firm fixed-price purchase order awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Geneimmune Biotechnology Corp, a for-profit Asian-Pacific American-owned biotechnology company based in Rockville, MD. The contract is for $151,620.00 and covers site-directed mutagenesis, gene synthesis, and plasmid preparation services in support of COVID-19 research. The contract was awarded on a sole-source basis pursuant to FAR 13.106-1 since Geneimmune Biotechnology Corp. has the base DNA samples and specialized capabilities required for this project. There is no set-aside designation for this contract. The award is associated with the NIH Vaccine Research Center's efforts to develop immunogens and neutralizing antibodies for HIV-AIDS vaccine research and clinical trials.
Quick answers
Who was awarded contract 75N93021P01324?
75N93021P01324 was awarded to Geneimmune Biotechnology Corp by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 5, 2021.
How much is contract 75N93021P01324 worth?
The government has obligated $151,620 on 75N93021P01324.
Was contract 75N93021P01324 competed?
The extent of competition for 75N93021P01324 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award